Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION-827359 Phase 2a in COPD with chronic bronchitis
2020-000210-15Phase 2Unknown
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing ION-827359 with Placebo (2 arms). Primary endpoint: Change from baseline in FEV1 at primary time point versus placebo. Status: unknown.
02
Drugs
cofirasersen
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on 2020-000210-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000210-15.